Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer
Breast Cancer: Targets and Therapy · 2026-07 · Volume 18 · 1-24
DOI: 10.2147/bctt.s606551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Targets and Therapy, 2026-07. Verfasst von Busra Aydin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Faculty of Engineering and Architecture, Konya Food and Agriculture University, Konya, Turkey. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Breast cancer (BC) is a highly heterogeneous malignancy, and current treatments often suffer from toxicity, limited selectivity, and high cost. This study aimed to integrate transcriptome-level data, multi-layered network analysis, and drug repositioning strategies to identify candidate diagnostic and prognostic biomarkers for BC and propose potential repositioned drug candidates.
Methods
Differentially expressed genes (DEGs) were identified from the GSE42568 dataset (|log 2 FC| > 1 and p < 0.05). Functional enrichment analyses were conducted using GO and KEGG. Three biological interaction layers - protein–protein interactions, transcription factors, and miRNA-mRNA interactions were constructed, and hub nodes were identified using topological metrics. Kaplan-Meier analyses assessed survival associations. PCA evaluated sample separation across datasets in GSE42568, GSE113865, and GSE22820. Drug repositioning was performed using L1000CDS 2 , and in vitro validation of a top drug candidate (niclosamide) and an exploratory comparative compound (amitriptyline) was performed using MCF-7 cells, including viability and combination assays.
Results
A total of 4266 DEGs were identified. Network analyses revealed 37 hub signatures, 11 of which— ESR1, RECQL4, FOS, BCL2, CXCL8, TRIM25, EGR1, CDH1, KRAS, PTGS2 , and IL6 were associated with survival outcomes. PCA demonstrated clear separation between healthy and BC samples. Drug repositioning identified eight candidates, with niclosamide as the top hit. In vitro assays showed marked reduction in cell viability at 5 μM niclosamide and 25 μM amitriptyline after 24 h treatment. No significant additive effect was observed in the combination treatment.
Conclusion
This integrative approach revealed candidate BC-specific biomarkers and identified niclosamide as a potential repositioned therapeutic. These findings remain exploratory and do not provide definitive clinical evidence. Further validation across additional models and clinical settings is required. Keywords: transcriptomics, biomarkers, breast cancer, drug repositioning, amitriptyline, niclosamide
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Bioengineering, Faculty of Engineering and Architecture, Konya Food and Agriculture University, Konya, Turkey.
- Department of Biotechnology, Institute of Postgraduate Education, Konya Food and Agriculture University, Konya, Turkey.
- Department of Molecular Biology and Genetics, Faculty of Agriculture and Natural Sciences, Konya Food and Agriculture University, Konya, Turkey.
- Department of Molecular and Precision Medicine, Penn State College of Medicine, Hershey, PA, USA.
ORCID-Profile: Busra Aydin, Beyza Nur Okutan, Raghu Sinha
Zitieren
APA
Aydin, B., Okutan, B. N., Sara, F. E., Gulseren, G., & Sinha, R. (2026). Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer. Breast Cancer: Targets and Therapy, Volume 18, 1-24. https://doi.org/10.2147/bctt.s606551
Vancouver
Aydin B, Okutan BN, Sara FE, Gulseren G, Sinha R. Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer. Breast Cancer: Targets and Therapy. 2026;Volume 18:1-24. doi:10.2147/bctt.s606551
BibTeX
@article{Aydin2026,
author = {Aydin, Busra and Okutan, Beyza Nur and Sara, Fatmanur Elif and Gulseren, Gulcihan and Sinha, Raghu},
title = {Integrative Network-Based Transcriptomic Analysis Identifies Niclosamide as a Candidate Repositioned Drug for Breast Cancer},
journal = {Breast Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 18},
pages = {1--24},
doi = {10.2147/bctt.s606551}
}
EUVIMED